Waters Corporation
Analysis
Waters turned its core business into a high-single-digit grower, then bought BD's biosciences and diagnostics units and fixed their sales execution faster than promised. The story now hinges on whether those businesses can be lifted to Waters' own growth and margins.How much of Waters' acquired-business turnaround is pricing rather than volume?
- The core business is now a high-single-digit grower, not a mid-single-digit one.
Waters has grown high single digits for seven quarters, and the first half of 2026 ran at 10%. Instruments are only back to a 2.5% yearly rate since 2019, so the replacement cycle has years left — the base business carries the story.How much of the instrument recovery is replacements rather than brand-new labs?
- The businesses Waters just bought are recovering faster than the deal assumed.
The BD units Waters bought in February were shrinking. They went flat, then grew 4% in Q2 FY2026, helped by better pricing and manufacturing localised in China. Management calls it A-plus and expects them to exit the year above 6%.
- Owning the deal made Waters a slower-growing, lower-margin company.
The combined company is guided to grow more slowly than the legacy business alone, and the acquired units earn nine points less on each dollar of sales. Interest and deal charges turned reported earnings negative, so profit trails sales.How much of the earnings drag is interest versus the extra shares issued?
- Instrument replacement cycleAged instrument fleets at large pharma and contract manufacturers still need years of replacement, so growth rests on a multiyear refresh rather than one good year.
- Bioseparations chemistry growthConsumables sell into every installed instrument, and management says new bioseparation chemistry has raised that business's long-run growth rate, not just one quarter.
- Acquired divisions grow fasterThe acquired businesses already grew faster in their first full quarters under Waters, as pricing discipline, funnel reviews and service attachment began to take hold.
- Acquired business margin mixThe bear case is that the acquisition permanently lowers margins and returns, since the acquired businesses earn far less per dollar of sales and came with heavy debt.
- China diagnostics reimbursementMuch of the acquired diagnostics revenue sits in China, where reimbursement changes and export licensing keep cutting growth, and local manufacturing only helps late this year.
- Turnaround execution riskThe turnaround depends on management fixing two new divisions at once, so slippage in pricing actions or launches would leave the combined company growing only modestly.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Sale | ≥$15K | Jun 12 | Aug 22 |
Donald Trump Republican · Executive | Purchase | ≥$1K | Mar 23 | May 13 |
Donald Trump Republican · Executive | Purchase | ≥$15K | Mar 18 | May 13 |
Donald Trump Republican · Executive | Purchase | ≥$15K | Mar 2 | May 13 |
Donald Trump Republican · Executive | Sale | ≥$100K | Feb 11 | May 13 |
Congressional trading data provided by QuiverQuant
How Waters turned $3.2B of revenue into $802.6M of operating income.
| Revenue | ||
|---|---|---|
| Waters Instrument Systems | $1.1B | ▲ 6.72% YoY |
| Waters Service | $1.1B | ▲ 7.32% YoY |
| Chemistry Consumables | $631.5M | ▲ 11.67% YoY |
| Ta Instrument Systems | $243.8M | ▼ 0.97% YoY |
| Ta Service | $108.0M | ▲ 0.24% YoY |
| Total revenue | $3.2B | |
| Gross profit | $1.9B | 59.3% |
| Operating income | $802.6M | 25.4% |